Search

EHA: Bridging Breakthroughs in Hematology

The European Hematology Association (EHA) has undergone a remarkable transformation over the past two years, positioning itself as a future-ready organization dedicated to addressing the needs of the European hematology community.

Read more

Previous winners, 2012–2022

2022 winners
Alexandre Fagnan
Junior Research Grant 2022
Deciphering the chromatin remodeling mechanism mediated by GATA2 ZnF1 mutations in AML

Samuele Ferrari
Junior Research Grant 2022
Innovative targeted base editing strategies for gene correction of WHIM syndrome

Lars Velten
Advanced Research Grant 2022
The role of the DNA methylation…

Read more

EHA has joined the European Cancer Organisation - a perfect match on objectives and prioritization

The European Hematology Association (EHA) has joined the European Cancer Organisation, a not-for-profit federation of organizations working in cancer at the European level.

Read more

Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma in the POLLUX Study

Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.

Read more

TARGETING THE JAK-STAT PATHWAY IN MALIGNANT AND NON-MALIGNANT CELLS IN MYELOPROLIFERATIVE NEOPLASMS

Myeloproliferative neoplasms (MPN) are clonal blood disorders characterized by excessive production of mature blood cells. Patients present with large spleens, systemic symptoms, and high levels of circulating inflammatory cytokines.

Read more

European Hematology Association tentatively responds to the European Commission’s proposal to improve clinical research

In addition, the regulation appears to accommodate multi-national trials with, for instance, a harmonized authorization dossier, and a single submission system.

Read more